Aducanumab

阿杜卡尼单抗

Report date: 2024/03/13 17:18:08

Base Information

Drug NameAducanumab
Drug Alias NameAducanumabum阿度卡人单抗阿度努单抗aducanumab-avwaADUHELM +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Global Approved IndicationsAlzheimer Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/06/07
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesNeurimmune Ag
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncEisai Co Ltd
Inactive CompaniesVetter Pharma-Fertigung Gmbh & Co KgBojian Biotechnology (Shanghai) Co Ltd
Active IndicationsAlzheimer Disease
Inactive IndicationsCognitive DysfunctionDementia

Other Information

ATC CodeN07
Related LinksWikipediaDrugBankKEGG